Clinical Trials
15 trialsNCT05171075 2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3 Terminated
NCT05171049 2026-02-23
ASTER
Anthos Therapeutics, Inc.
Phase 3 Terminated
NCT03297359 2024-01-23
WAVe
Ottawa Hospital Research Institute
Phase 2 Terminated
NCT03090880 2022-11-17
PROVE
Assistance Publique - Hôpitaux de Paris
Phase 3 Terminated
NCT02583191 2021-05-03
Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients
AIO-Studien-gGmbH
Phase 3 Terminated
NCT04106700 2021-02-15
Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs
Instituto de Investigacion Sanitaria La Fe
Phase 2 Terminated
NCT03006562 2020-08-05
PREVENTER
Johns Hopkins University
Phase 4 Terminated
NCT03471468 2020-02-17
DOMICA
Poitiers University Hospital
Phase NA Terminated
NCT03195010 2019-10-21
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT01817257 2018-10-29
ALICAT
Cardiff University
Phase 2 Terminated
NCT00981903 2017-07-06
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
University of Southern California
Phase 2 Terminated
NCT00876915 2015-11-24
PHACS
University of Rochester
Phase 3 Terminated
NCT01608919 2015-08-10
Predictive Value of Whole Blood Coagulation Parameters for Post-discharge Venous Thromboembolism After Cancer Resection
University of Colorado, Denver
Phase NA Terminated
NCT01164046 2014-12-03
Longheva
University Medical Center Groningen
Phase 3 Terminated
NCT00790452 2011-12-08
Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma
M.D. Anderson Cancer Center
Phase 2 Terminated